NEW YORK--(BUSINESS WIRE)--Microlin Bio, Inc., a development stage biotechnology company focused on microRNA based therapeutics for the treatment of cancer, announced today positive results from preclinical studies using their lead anti-microRNA candidate in a murine lung cancer model. For these preclinical studies, anti-miR-21 (AM-21) was delivered using the company’s novel QTsome® (QT) delivery platform, which is composed of a combination of two cationic lipids with tertiary and quaternary am
| < Prev | Next > |
|---|
